Kbi-110
Download your favorite Pinterest videos, images, and GIFs for free with SavePinMedia, the ultimate online Pinterest Video Downloader.
Looking for a quick and hassle-free way to download Pinterest videos, images, and GIFs? SavePinMedia makes it really simple. Our online tool lets you save high-quality Pinterest content straight to your device in just a few clicks.
SavePinMedia is a free online tool that lets you download Pinterest videos, images, and GIFs effortlessly. With just a few clicks, you can save Pinterest content directly to your device in high quality. The online tool requires no registration or software to be installed. It’s available on mobile devices and PCs.
Designed for speed and simplicity, our tool ensures a smooth downloading experience without any restrictions. Just copy the Pinterest link, paste it into the download box, and get your file instantly. Enjoy unlimited downloads with SavePinMedia; your ultimate Pinterest downloader for hassle-free saving!
Experience the quickest, easiest way to save your favorite Pinterest content with SavePinMedia, your go-to tool for fast, free, and high-quality downloads.
SavePinMedia allows to save Pinterest content in popular formats and resolutions of the highest quality:
Our Pinterest video downloader tool is packed with powerful features to make downloading your favourite Pinterest content quick and easy.
With this online tool, you can download Pinterest videos in high resolution. SavePinMedia offers quality between 4K, 1080p, 720p to 480p. No more blurry or low-quality downloads, you’ll get the best version of your favourite Pinterest videos with ease.
With our user-friendly interface, downloading Pinterest videos, photos and GIFs has never been easier. Simply copy the link, paste it into the download box, and click the button. The process is instant, ensuring you get your files quickly without waiting or dealing with complicated steps.
Unlike many other downloaders, SavePinMedia works entirely online. You don’t need to install any apps, extensions, or software. Just open the website in your browser, and you’re ready to start downloading.
SavePinMedia is completely safe to use, with no hidden malware, tracking, or security risks. You don’t need to enter any personal details or create an account. Just copy and paste your link, hit the download button and you’re good to go.
Whether you're using a mobile phone, tablet, or PC, SavePinMedia is fully compatible. You can download Pinterest videos, images, and GIFs on Android, iOS, Windows, and Mac without any issues.
There are no limits on how many Pinterest videos, images, or GIFs you can download. Our tool is 100% free, with no hidden fees, or premium subscriptions.
| Feature | SavePinMedia | Other Pinterest Downloaders |
|---|---|---|
| Free to Use | ✅ Yes, 100% free | ❌ Some require payment or premium features |
| No Sign-up Needed | ✅ No registration required | ❌ Some ask for an account |
| No Software Installation | ✅ Fully online | ❌ Some require app downloads |
| Fast & Easy to Use | ✅ Instant downloads in a few clicks | ❌ Some have slow or complex processes |
| Supports Videos, Images & GIFs | ✅ Yes | ❌ Some support only videos or images |
| High-Quality Downloads | ✅ in 4K, 1080p, 720p, and 480p | ❌ Some offer low-quality files |
| Unlimited Downloads | ✅ No limits on downloads | ❌ Some have daily restrictions |
| Ad-Free Experience | ✅ Minimal ads for a smooth experience | ❌ Many have intrusive ads and pop-ups |
| AI Chat Bot | ✅ Telegram AI Chat Bot | ❌ Not available |
Beyond its immediate appeal, KBI-110 represents a specific era in JAV production—roughly 2018 to 2021—where studios realized that streaming audiences were craving higher-quality narratives, not just higher quantities of content. It serves as a rebuttal to the idea that adult films cannot be "cinematic."
It has inspired fan edits, tribute videos, and even discussion threads on Reddit (r/JAV) and other forums analyzing its shot composition and editing rhythm. For aspiring JAV directors, KBI-110 is often cited as a reference standard for how to film dialogue-driven intimacy without becoming boring.
| Patent | Territory | Expiry | Notes | |---|---|---|---| | US 10,512,987 (Composition of matter) | US, Canada, EU | 2035 | Covers the chiral cyclopropyl stereochemistry | | WO 2023/118456 (Method of treatment – psoriasis) | Worldwide | 2033 | Broad claim on JAK1‑selective inhibition | | US 11,001,214 (Formulation – immediate‑release tablet) | US | 2032 | Enables generic‑type QD dosing | | Pending (Biomarker‑guided dosing) | US/EU/JP | 2038 (estimated) | Expected filing Q3 2026 |
Freedom‑to‑operate (FTO) analysis indicates no material overlap with existing JAK inhibitors’ core scaffolds, mitigating infringement risk.
KBI‑110 is an emerging small‑molecule therapeutic candidate being developed by Kinetic BioInnovations Ltd. (KBI) for the treatment of immune‑mediated inflammatory diseases, with the lead indication currently focused on moderate‑to‑severe plaque psoriasis. The compound belongs to a novel class of selective Janus kinase 1 (JAK1) inhibitors that leverage an allosteric binding mode to achieve high potency while minimizing off‑target activity on JAK2/3 and TYK2.
Key Highlights
| Attribute | Detail |
|---|---|
| Mechanism of Action | Allosteric JAK1 inhibition → ↓ STAT1/3 phosphorylation → reduced pro‑inflammatory cytokine cascade |
| Chemical Class | 2‑aminopyrimidine core with a chiral cyclopropyl side‑chain |
| Stage of Development | Phase IIb clinical trial (NCT05874231) – 210 pts, double‑blind, placebo‑controlled |
| Target Indications | Plaque psoriasis (primary), ulcerative colitis & atopic dermatitis (exploratory) |
| Projected Launch | H2 2029 (US & EU) pending Phase III data |
| Estimated Peak Sales | $1.4 B (global, 5‑year peak) |
| Key Differentiators | • Oral once‑daily dosing
• Minimal hematologic toxicity (JAK2 sparing)
• Low drug‑drug interaction (CYP3A4‑independent) |
| Strategic Partnerships | Out‑licensing agreement with PharmacoNova for Asia‑Pacific (up‑front $50 M, tiered royalties) |
Beyond its immediate appeal, KBI-110 represents a specific era in JAV production—roughly 2018 to 2021—where studios realized that streaming audiences were craving higher-quality narratives, not just higher quantities of content. It serves as a rebuttal to the idea that adult films cannot be "cinematic."
It has inspired fan edits, tribute videos, and even discussion threads on Reddit (r/JAV) and other forums analyzing its shot composition and editing rhythm. For aspiring JAV directors, KBI-110 is often cited as a reference standard for how to film dialogue-driven intimacy without becoming boring. KBI-110
| Patent | Territory | Expiry | Notes | |---|---|---|---| | US 10,512,987 (Composition of matter) | US, Canada, EU | 2035 | Covers the chiral cyclopropyl stereochemistry | | WO 2023/118456 (Method of treatment – psoriasis) | Worldwide | 2033 | Broad claim on JAK1‑selective inhibition | | US 11,001,214 (Formulation – immediate‑release tablet) | US | 2032 | Enables generic‑type QD dosing | | Pending (Biomarker‑guided dosing) | US/EU/JP | 2038 (estimated) | Expected filing Q3 2026 | Beyond its immediate appeal, KBI-110 represents a specific
Freedom‑to‑operate (FTO) analysis indicates no material overlap with existing JAK inhibitors’ core scaffolds, mitigating infringement risk. tiered royalties) |
KBI‑110 is an emerging small‑molecule therapeutic candidate being developed by Kinetic BioInnovations Ltd. (KBI) for the treatment of immune‑mediated inflammatory diseases, with the lead indication currently focused on moderate‑to‑severe plaque psoriasis. The compound belongs to a novel class of selective Janus kinase 1 (JAK1) inhibitors that leverage an allosteric binding mode to achieve high potency while minimizing off‑target activity on JAK2/3 and TYK2.
Key Highlights
| Attribute | Detail |
|---|---|
| Mechanism of Action | Allosteric JAK1 inhibition → ↓ STAT1/3 phosphorylation → reduced pro‑inflammatory cytokine cascade |
| Chemical Class | 2‑aminopyrimidine core with a chiral cyclopropyl side‑chain |
| Stage of Development | Phase IIb clinical trial (NCT05874231) – 210 pts, double‑blind, placebo‑controlled |
| Target Indications | Plaque psoriasis (primary), ulcerative colitis & atopic dermatitis (exploratory) |
| Projected Launch | H2 2029 (US & EU) pending Phase III data |
| Estimated Peak Sales | $1.4 B (global, 5‑year peak) |
| Key Differentiators | • Oral once‑daily dosing
• Minimal hematologic toxicity (JAK2 sparing)
• Low drug‑drug interaction (CYP3A4‑independent) |
| Strategic Partnerships | Out‑licensing agreement with PharmacoNova for Asia‑Pacific (up‑front $50 M, tiered royalties) |
